LCB84 + anti-PD-1 monoclonal antibody

LCB84 + anti-PD-1 monoclonal antibody is an investigational combination therapy being evaluated for the treatment of advanced solid tumors. **LCB84** is a next-generation antibody-drug conjugate (ADC) that targets TROP2, a cell surface glycoprotein highly expressed in various epithelial cancers. LCB84 consists of a humanized IgG1 monoclonal antibody (Hu2G10) specific for ADAM10-activated TROP2, conjugated via a plasma-stable linker to the cytotoxic payload monomethyl auristatin E (MMAE). This allows for targeted and efficient release of MMAE within tumor cells. **Anti-PD-1 monoclonal antibody** (such as pembrolizumab, though the specific molecule is not named in the trial synopsis) is an immune checkpoint inhibitor that blocks the programmed cell death protein 1 (PD-1) pathway, enhancing T-cell mediated antitumor immune responses. The combination is being assessed in a first-in-human Phase 1/2 study for safety, tolerability, and preliminary efficacy, with sequential dose escalation after LCB84 monotherapy cohorts. The goal is to determine the recommended phase 2 dose and to evaluate potential synergistic effects between TROP2-directed cytotoxic therapy and PD-1 blockade[1][2][3][4][6].

Other names

TROP2 ADC LCB84 + anti-PD-1 monoclonal antibody